Owkin

Owkin is an AI biotech company founded in 2016 by Thomas Clozel, MD, and Gilles Wainrib, PhD, with a mission to unlock complex biology and find the right treatment for every patient. The company is pioneering what it calls Biological Artificial Superintelligence — advanced agentic AI, biological reasoning models, specialized AI skills, and intelligent orchestration designed to process complex patient data and discover new biology. Owkin's vision is a world where R&D is automated and research is directly connected to care, addressing the fundamental challenge that untangling biology's complexity is beyond the limits of human intelligence alone.

Owkin operates across drug discovery, drug development, and diagnostics, serving top biopharma companies, academic institutions, and clinical partners globally. The company has established strategic deals with top-8 biopharma organizations including Sanofi (AI drug discovery), BMS (AI drug development), and MSD (AI diagnostics), and has raised over $304 million from investors including F-Prime, Google Ventures, Bpifrance Large Ventures, Sanofi, and BMS. Owkin maintains offices in Boston, New York, London, Paris, Nantes, Geneva, and Berlin, and works with 83 academic partners across Canada, the USA, France, Germany, and Spain.

K Pro — Agentic AI for Drug Discovery and Development

• K Pro is Owkin's flagship AI agent, designed to drive insight generation and decision-making across drug discovery and development.
• It is described as the first AI agent connecting research and care, delivering answers in minutes rather than hours.
• K Pro continuously learns from real-world data, user feedback, and clinical validation, evolving toward fully automated R&D.
• It is built on a patient data network, ensuring AI predictions are validated in real-world patients and refined through outcomes and clinical review.
• K Pro serves as Owkin's stepping stone toward achieving Biological Artificial Superintelligence — a future community of automated AI scientists guided by top researchers worldwide, capable of hypothesizing, planning, and running experiments in parallel.
• Owkin's long-term vision is a network of millions of AI scientists that will usher in a new age of biological understanding.

AI-Powered Drug Discovery

• Owkin develops state-of-the-art, AI-based computational technologies using rich multimodal patient data to discover new treatments.
• The company uses patient data as the foundation for all AI development, ensuring real-world impact and direct connection between research and clinical care.
• Drug discovery AI engines are designed to identify new drug candidates and accelerate the path from biological insight to therapeutic intervention.
• Owkin's scientific output includes publications in top-tier journals such as Nature Medicine, Nature Communications, and Hepatology.

AI-Powered Drug Development

• Owkin combines cutting-edge machine learning and biology to de-risk and accelerate clinical trials.
• The company recently created a new spin-out called Waiv (formerly Owkin Dx), which received $33 million in financing as of March 2026, focused on advancing drug development capabilities.
• Owkin's development solutions are designed to reduce uncertainty and improve the efficiency of clinical trial design and execution.

AI Diagnostics and Digital Pathology

• Owkin delivers AI diagnostic solutions that integrate seamlessly into digital pathology workflows to support accurate and timely diagnosis.
• MSIntuit® CRC is a CE-marked, first-in-class AI diagnostic that screens for microsatellite instability (MSI) in colorectal cancer using only digitized H&E slides.
• RlapsRisk® BC is an AI tool that helps pathologists and oncologists determine the right treatment pathway for early breast cancer patients.
• A published case study, MesoNet, demonstrates Owkin's AI capabilities in biomarker-based outcome prediction in mesothelioma.

Patient Data Network and Validation

• Owkin's AI is grounded in a patient data network that connects research directly to real-world clinical outcomes.
• All AI models are validated in real-world patients, with continuous learning from outcomes, feedback, and clinical review to refine predictions and accelerate decisions.
• This patient validation approach distinguishes Owkin's platform from purely computational or preclinical AI systems.

Scientific Credibility and Team

• Owkin is founder-led, with Thomas Clozel, MD (Oncologist) and Gilles Wainrib, PhD (Professor of Machine Learning) at the helm.
• The company employs 357 team members, including leading experts in data access and data science, medical doctors, biostatisticians, and computational biologists.
• A Scientific Advisory Board of top disease-area specialists is chaired by Miriam Merad, MD, PhD, of the Mount Sinai School of Medicine in New York City.
• Owkin maintains close relationships with 141 Key Opinion Leaders (KOLs) with a mean H-index of 49, as well as 83 academic partners across North America and Europe.

Owkin's integrated approach — combining agentic AI, multimodal patient data, rigorous clinical validation, and deep scientific partnerships — positions it as a leading force in the transformation of drug discovery, development, and diagnostics across the life sciences industry.